ImmunityBio stock jumps in premarket as $113 mln ANKTIVA sales update fuels rally
ImmunityBio shares surged 32% premarket after reporting preliminary 2025 product revenue of $38.3 million for Q4, up 20% from Q3 and 431% year over year. Saudi regulators granted accelerated approval for ANKTIVA in lung and bladder cancer. The company ended the quarter with $242.8 million in cash. Revenue figures are unaudited and may change.